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Abstract: BACKGROUND: The transforming growth factor-beta (TGF-beta) pathway, which has both
tumor suppressor and pro-oncogenic activities, is often constitutively active in melanoma and is a marker
of poor prognosis. Recently, we identified GLI2, a mediator of the hedgehog pathway, as a transcriptional
target of TGF-beta signaling. METHODS: We used real-time reverse transcription-polymerase chain
reaction (RT-PCR) and western blotting to determine GLI2 expression in human melanoma cell lines
and subsequently classified them as GLI2high or as GLI2low according to their relative GLI2 mRNA and
protein expression levels. GLI2 expression was reduced in a GLI2high cell line with lentiviral expression of
short hairpin RNA targeting GLI2. We assessed the role of GLI2 in melanoma cell invasiveness in Matrigel
assays. We measured secretion of matrix metalloproteinase (MMP)-2 and MMP-9 by gelatin zymography
and expression of E-cadherin by western blotting and RT-PCR. The role of GLI2 in development of bone
metastases was determined following intracardiac injection of melanoma cells in immunocompromised
mice (n = 5-13). Human melanoma samples (n = 79) at various stages of disease progression were
analyzed for GLI2 and E-cadherin expression by immunohistochemistry, in situ hybridization, or RT-PCR.
All statistical tests were two-sided. RESULTS: Among melanoma cell lines, increased GLI2 expression
was associated with loss of E-cadherin expression and with increased capacity to invade Matrigel and to
form bone metastases in mice (mean osteolytic tumor area: GLI2high vs GLI2low, 2.81 vs 0.93 mm(2),
difference = 1.88 mm(2), 95% confidence interval [CI] = 1.16 to 2.60, P < .001). Reduction of GLI2
expression in melanoma cells that had expressed high levels of GLI2 substantially inhibited both basal
and TGF-beta-induced cell migration, invasion (mean number of Matrigel invading cells: shGLI2 vs
shCtrl (control), 52.6 vs 100, difference = 47.4, 95% CI = 37.0 to 57.8, P = .024; for shGLI2 + TGF-beta
vs shCtrl + TGF-beta, 31.0 vs 161.9, difference = -130.9, 95% CI = -96.2 to -165.5, P = .002), and
MMP secretion in vitro and the development of experimental bone metastases in mice. Within human
melanoma lesions, GLI2 expression was heterogeneous, associated with tumor regions in which E-cadherin
was lost and increased in the most aggressive tumors. CONCLUSION: GLI2 was directly involved in
driving melanoma invasion and metastasis in this preclinical study.
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Melanoma represents approximately 4% of human skin cancers, 
yet accounts for approximately 80% of deaths from cutaneous 
neoplasms (1). Although progress has been made in understanding 
the genetics of the molecular events underlying melanoma onco-
genesis (2–4), the clinical challenge remains enormous. A genetic 
hallmark of melanoma is the presence of activating mutations in 
the oncogenes BRAF and NRAS, which are present in 70% and 
15% of melanomas, respectively, and lead to constitutive activation 
of mitogen-activated protein kinase pathway signaling (3,5). 
However, molecules that inhibit mitogen-activated protein kinase 
pathway–associated kinases, like BRAF and MEK, have shown 
only limited efficacy in the treatment of metastatic melanoma (6). 
Thus, a deeper understanding of the cross talk between signaling 
networks and the complexity of melanoma progression should lead 
to more effective therapy.
Hedgehog (HH) signaling is controlled at the cell surface by 
two transmembrane proteins, the tumor suppressor Patched-1 
(PTCH1), which acts as a HH receptor, and the oncoprotein 
Smoothened (SMO). In the absence of HH, PTCH1 maintains 
SMO in an inactive state. In the presence of any of the three HH 
ligands (Sonic, Indian, or Desert HH), inhibition of SMO by 
PTCH1 is alleviated and a signal is transduced that leads to the 
nuclear translocation and activation of GLI family transcription 
factors (7,8). GLIs are often overexpressed in cancers and contrib-
ute to the progression of a variety of neoplasms via regulation of 
cell cycle progression and apoptosis (9,10). One recent study (11) 
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suggested that the HH pathway may play a role in melanoma pro-
gression based on pharmacological inhibition of HH signaling in 
genetic mouse models of melanoma.
Transforming growth factor-b (TGF-b) is a potent inhibitor 
of normal epithelial cell proliferation. However, it is secreted in 
abundance by tumor cells and exerts pro-oncogenic activities in 
later stages of tumor progression (12–14). Members of the 
TGF-b superfamily signal via heteromeric serine/threonine 
kinase transmembrane receptor complexes that, on ligand 
binding, phosphorylate SMAD family proteins that mediate sig-
naling from the cell membrane to the nucleus (15,16). In vivo, 
malignant melanomas secrete high amounts of TGF-b, and 
increased circulating plasma concentrations of TGF-b are asso-
ciated with the advancing stage of the tumor (17,18). TGF-b also 
exerts paracrine effects on angiogenesis and immune surveillance, 
thereby promoting tumor growth and survival (19). Autocrine 
TGF-b signaling and SMAD-dependent transcriptional re-
sponses directly exacerbate melanoma cell tumorigenicity and 
metastasis (20–22).
Recently, we determined that the gene for GLI2, which is the 
most transcriptionally active of the GLI proteins, was directly 
induced by TGF-b and SMAD signaling (23). Furthermore, the 
GLI2 protein mediates the induction of GLI1 expression in 
response to TGF-b, independent of HH signaling (23).
In this report, we have analyzed the specific role played by 
GLI2 in human melanoma. We used a combination of in vitro and 
in vivo experimental approaches to determine whether GLI2 ex-
pression is associated with melanoma cell invasion, matrix metal-
loproteinase (MMP) secretion, expression of E-cadherin, and 
metastasis to bone. Reduction of GLI2 expression with specific 
short hairpin RNA (shRNA) vectors was used to directly address 
the functionality of GLI2 in these experimental settings. To gain 
insight into the pathophysiological relevance of our findings in 
melanoma, expression of GLI2, together with that of E-cadherin, 
was determined in human melanoma tumors.
Materials and Methods
Cell Cultures and Reagents
Human melanoma cell lines that were derived from tumor biopsies 
from patients with either primary (WM793, 888mel, Dauv1, and 
WM983A) or metastatic (WM983B [same patient as WM983A], 
WM852, 501mel, FO-1, and SK28) melanoma lesions were grown 
in RPMI 1640 (Invitrogen, Carlsbad, CA) supplemented with 10% 
fetal calf serum (FCS) and antibiotics. 1205Lu melanoma cells 
were derived from WM793 cells by serial passage through athymic 
mice and selection of cells metastatic to the lungs. WM cell lines 
were a gift from Meenhard Herlyn (Wistar Institute, Philadelphia, 
PA). FO-1 cells were a gift from Renato Baserga (Thomas Jefferson 
University, Philadelphia, PA). 888mel and SK28 cell lines were 
purchased from American Type Culture Collection (Manassas, 
VA). Dauv1 cells were a gift from Benoit van den Eynde (Ludwig 
Institute for Cancer Research, Brussels, Belgium). All cell lines in this 
panel carry an activating mutation of the BRAF gene, except for 
WM852 cells, which carry an activating mutation of NRAS (24). 
Additional details may be found in previous publications (20,22,25–
27). Normal human foreskin epidermal melanocytes (passages 5–8) 
were purchased from PromoCell GmbH (Heidelberg, Germany). 
All melanocyte cell lines were verified to express melanocyte-
microphthalmia-associated transcription factor (M-MITF), a marker 
of the melanocytic lineage, at detectable levels by quantitative reverse 
transcription–polymerase chain reaction (RT-PCR). Lentiviral 
particles expressing GLI2 shRNAs were purchased from Sigma-
Aldrich (St Louis, MO). TGF-b1 was purchased from R&D Systems, 
Inc (Minneapolis, MN). Expression vectors carrying dominant-
negative and constitutively active versions of mouse GLI2 and the 
GLI-specific reporter plasmid (GLI-BS)8-luc were gifts from 
H. Sasaki (Osaka University) and have been described previously 
(28,29). pRL-TK was from Promega (Madison, WI).
RNA Extraction and Gene Expression Analysis
Total RNA was isolated from cell cultures using an RNeasy kit 
(Qiagen GmbH, Hilden, Germany). Genomic DNA contamina-
tion was eliminated by DNase I treatment. One microgram of 
RNA was reverse transcribed using the Thermoscript kit 
(Invitrogen). The resulting cDNAs were then processed for either 
semiquantitative or real-time RT-PCR using either ethidium 
bromide staining of electrophoretically separated amplimers or 
SYBR Green technology (Applied Biosystems, Foster City, CA). 
In the latter case, reactions were carried out in a 7300 Real- 
Time PCR System (Applied Biosystems) for 40 cycles (95°C for 
cONteXt AND cAVeAtS
Prior knowledge
The gene for hedgehog pathway component GLI2 was reported to 
be induced by transforming growth factor-b signaling, which pro-
motes melanoma tumorigencitiy, but a role for GLI2 in melanoma 
invasion and metastasis had not been tested.
Study design
Melanoma cell lines that expressed high or low levels of GLI2 
(GLI2high vs GLI2low) or that expressed shRNA to GLI2 or consti-
tutively active GLI2 were compared in Matrigel invasion assays and 
in assays of bone metastasis after intracardiac injection of immu-
nocompromised mice. Levels of GLI2 expression were also exam-
ined in staged human melanoma tissue specimens.
Contribution
Elevated GLI2 expression was associated with greater invasiveness 
of melanoma cells in vitro and with increased number and size of 
osteolytic metastases in mice. Overall, GLI2 expression was 
increased in more aggressive tumors.
Implications
GLI2 may play a role in melanoma invasion and metastasis.
Limitations
Most experiments were done with melanoma cell lines in an in 
vitro invasion assay or in an immunocompromised mouse model 
of bone metastasis, whereas in immunocompetent humans, mela-
noma cells would most likely metastasize to lung, soft tissue, and 
brain. Evaluation of GLI2 in clinical specimens was limited by the 











1150   Articles | JNCI Vol. 102, Issue 15  | August 4, 2010
15 seconds and 60°C for 1 minute) after an initial 10-minute incu-
bation at 95°C. Data were analyzed using Applied Biosystems 
Sequence Detection Software (version 1.2.1) and normalized to 
cyclophilin A (PPIA) or glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) expression. Five independent experiments were 
performed to validate gene expression data in each cell line. Primer 
sequences for multiplex semiquantitative RT-PCR and for real-
time RT-PCR are provided in Supplementary Tables 1 and 2, 
respectively (available online).
Western Blotting
Protein extraction and western blotting were performed in three 
independent experiments as previously described (22). Goat poly-
clonal anti-GLI2 (sc-20291, 1:200 dilution); rabbit polyclonal anti-
E-cadherin (sc-7870, 1:500 dilution); and secondary donkey 
anti-mouse, anti-goat, and anti-rabbit horseradish peroxidase– 
conjugated antibodies were from Santa Cruz Biotechnology, Inc 
(Santa Cruz, CA). Mouse monoclonal anti-GAPDH (ab8245, 1:5000 
dilution) was from Abcam (Cambridge, MA), and anti-b-actin 
(A4700, 1:1000 dilution) was from Sigma-Aldrich.
Stable GLI2 Silencing in 1205Lu Human Melanoma Cells
Subconfluent 1205Lu cells were infected with lentiviruses that 
expressed either control, nontargeting, shRNA (shCtrl; Sigma-
Aldrich SHC002V) or shRNA targeting GLI2 (Sigma-Aldrich 
SHVRS clone ID TRCN0000033329 and TRCN0000033330) at 
a multiplicity of 8 plaque-forming units per cell in presence of 
8 µg/mL hexadimethrine bromide. Stably transduced cell popula-
tions were selected with puromycin (2 µg/mL). Efficient and stable 
reduction of GLI2 mRNA expression over time was verified by 
real-time RT-PCR after each passage and before experiments.
Stable Transfections
Truncated forms of mouse GLI2 that expressed GLI2 proteins 
with deletions of amino acids 1184–1544 (GLI2-DC2) or 1–279 
(GLI2-DN2) were used as dominant-negative and constitutively 
active GLI2 mutants, respectively (29). SK28 and 1205Lu mela-
noma cells were transfected at approximately 70%–80% conflu-
ence with 10 µg of either the empty expression vector (ctrl) or the 
same vector carrying constitutively active GLI2-DN2 or domi-
nant-negative GLI2-DC2 (29) per 100-mm-diameter culture dish 
using the polycationic compound Fugene (Roche Diagnostics, 
Indianapolis, IN) in fresh medium containing 1% FCS. Three 
days later, G418 (Sigma-Aldrich, 0.7 mg/mL) was added to the 
culture medium. Selection of stable clones occurred within a 
3-week period. Semiquantitative RT-PCR was used to verify the 
expression of the transfected gene constructs.
Transient Cell Transfections and Reporter Assays
SK28 melanoma cells were seeded in 24-well plates and cotrans-
fected with (GLI-BS)8-luc (28) and pRL-TK as a control for transfec-
tion efficiency (Promega). Cells were transfected at approximately 
70%–80% confluence using the polycationic compound Fugene 
(Roche Diagnostics) in fresh medium containing 1% FCS. 
Following a 16-hour incubation, cells were rinsed twice with 
phosphate-buffered saline (PBS) and lysed in passive lysis buffer 
(Promega). Luciferase activities were determined with a Dual-Glo 
luciferase assay kit according to the manufacturer’s protocol 
(Promega). In general, three independent experiments were per-
formed using triplicate samples, but the number varied among 
experiments and is detailed in the corresponding figure legends.
Matrigel Invasion Assays
Tissue culture Transwell inserts (8 µm pore size; Falcon, Franklin 
Lakes, NJ) were coated for 3 hours with 10 µg of growth factor– 
reduced Matrigel (Biocoat; BD Biosciences, San Jose, CA) in 100 µL 
of PBS at 37°C. After air-drying the chambers for 16 hours, the 
Matrigel barrier was reconstituted with 100 µL Dulbecco’s min-
imal essential medium for 24 hours at 37°C. The chambers were 
then placed into 24-well dishes containing 750 µL of RPMI me-
dium supplemented with 0.1% FCS. 5 × 104 melanoma cells 
(1205Lu, WM793, WM852, Dauv1, WM983A, WM983B, SK28, 
501mel, and 888mel) were added to the upper well of each 
chamber in 500 µL of serum-free RPMI medium. After a 24-hour 
incubation period, the number of invading cells was counted by 
bright field microscopy at ×200 in six random fields. Additional 
details of the procedure may be found in Javelaud et al. (21). 
Experiments were performed four times using duplicate samples.
Gelatin Zymography
The presence of MMP-2 and MMP-9 in serum-free conditioned 
media was analyzed by zymography in 10% sodium dodecyl sulfate– 
polyacrylamide gels containing 1 mg/mL gelatin (Sigma-Aldrich). 
After removal of sodium dodecyl sulfate with Triton X-100, 
neutral protease activity was revealed by incubation of the gels for 
48 hours at 37°C in 0.1 M Tris–HCl buffer (pH 7.4) containing 
10 mM CaCI2, followed by staining in 0.5% Coomassie blue in an 
aqueous solution containing 30% isopropanol and 10% acetic acid 
and destaining in 30% isopropanol and 10% acetic acid (30). 
Three independent experiments were performed.
Wound Closure Assays
For scratch wound assays, freshly confluent monolayers of shCtrl 
and shGLI2-transfected 1205Lu cells were wounded by manually 
scraping off cells with a sterile pipette tip. Following wounding of 
the monolayers, wound sizes were verified to ensure that they were 
all the same width (approximately 0.8 mm). The cell culture me-
dium was then replaced with fresh RPMI containing 4 µg/mL 
mitomycin C (Sigma-Aldrich), and wound closure was monitored 
over a 48-hour period with a phase contrast microscope at ×200 
magnification. Experiments were repeated three times.
Experimental Bone Metastasis in Mice
The protocols for bone metastasis experiments in athymic female 
nude mice were approved by the Institutional Animal Care and Use 
Committee at the University of Virginia in Charlottesville and were 
in accordance with the National Institutes of Health Guide for the 
Care and Use of Laboratory Animals. Harlan-Sprague-Dawley athy-
mic nude-Foxn Nu mice (nu/nu, n = 72) were purchased from 
Harlan (Indianapolis, IN). In brief, following anesthesia of each 
mouse by intraperitoneal injection with a mixture of 30% ketamine 
and 20% xylazine in 0.9% NaCl (7 mg/100 g body weight), the left 
cardiac ventricle was punctured percutaneously using a 26-gauge 
needle attached to a 1-mL syringe containing suspended tumor 
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cells. Visualization of bright red blood entering the hub of the 
needle in a pulsatile fashion indicated a correct position in the left 
cardiac ventricle. Tumor cells (105 in 0.1 mL of PBS) were inocu-
lated slowly over 1 minute. Mice were followed by radiography for 
the development of bone lesions throughout the experiments. Images 
were saved, and lesion areas were measured and analyzed using 
MetaMorph software (Molecular Devices, Downingtown, PA). 
Briefly, the images were calibrated, and the edges of the translucent 
area that represents area of bone loss were identified and traced with 
a computer mouse pointer, and the area was measured in squared 
millimeter units. Details of the experimental procedures may be found 
in several past publications (22,31–33). Mice bearing human tumor 
xenografts were carefully monitored for established signs of distress 
and discomfort including development of cachexia (as defined by loss 
of 20% of original body weight) and inability of the mouse to move 
and reach for the food source and were humanely killed when these 
were confirmed.
Immunohistochemistry and In Situ Hybridization on 
Human Tissues
Formaldehyde-fixed and paraffin-embedded melanomas (n = 20) 
from adult patients were obtained from the pathology archives of 
the Radboud University Nijmegen Medical Centre. All specimens 
were reevaluated by an expert pathologist. Tissues were obtained 
according to local ethical guidelines and approved by the local 
regulatory committee. Paraffin-embedded 4-µm sections were 
dewaxed and rehydrated through graded alcohol baths. After an 
antigen retrieval step with Tris-buffered EDTA (1 mM, pH 9.0, 
for 10 minutes at 95°C), tissue paraffin sections were preincubated 
with 20% normal horse serum and subsequently incubated with a 
mouse monoclonal antibody directed against E-cadherin 
(Neomarkers, clone SPM471, 1:300 dilution) in PBS containing 
1% bovine serum albumin overnight at 4°C. As a secondary 
reagent, a horseradish peroxidase–conjugated goat anti-mouse 
antibody from the Powervision system (Immunovision Labs, 
Brisbane, CA) was used at a 1:2 dilution. Diaminobenzidine served 
as a chromogen. Counterstaining was performed with 
hematoxylin.
For in situ hybridization, a 340-bp human GLI2 cDNA frag-
ment was generated by RT-PCR. Briefly, total RNA isolated from 
1205Lu melanoma cells was isolated with Trizol (Invitrogen) 
according to the manufacturer’s protocol, and 1 µg was reverse 
transcribed at 42°C for 1 hour using SuperScript II (Invitrogen) 
and oligo dT primers. First strand 5′ cDNA samples were am-
plified using oligonucleotide primer pairs (5′-AGTTTGTTCT 
CGGGTGCTCTG-3′ and 5′-ACATCTGTCATCTGAAGC 
GGC-3′) based on the reported sequence of human GLI2 
(GenBank accession number NM005270). Amplification con-
sisted of preincubation at 95°C for 5 minutes before adding Taq 
polymerase followed by 30 cycles at 95°C for 1 minute, 60°C for 
30 seconds, and 72°C for 30 seconds. A PCR product of the pre-
dicted size was cloned into the pGEM-T easy vector (Promega), 
and the sequence was verified. The plasmid was linearized by di-
gestion with PstI or SphI. Antisense and sense digoxygenin-labeled 
rUTP riboprobes were synthesized using T7 and SP6 RNA poly-
merase, respectively, according to standard procedures. The in situ 
hybridization procedure was performed as described earlier (34) 
using tissue sections adjacent to those used for anti-E-cadherin or 
hematoxylin and eosin staining.
Tissue Harvesting and Total RNA Isolation
Tumor samples were obtained through the Tissue Retrieval 
Service of the Cancer Institute of New Jersey, following ethical 
committee guidelines of the University of Medicine and Dentistry 
of New Jersey (UMDNJ)-Robert Wood Johnson Medical School 
Institutional Review Board (n = 42), and from the tissue bank at 
Hôpital Ambroise Paré under the supervision of the local ethical 
committee (Comité de Protection des Personnes IDF8) (n = 17). 
Tissue samples were collected such that no patient-identifiable 
information was included with the specimens, but tumor location 
and stage were recorded. Details have been described previously 
(35). Tumor specimens from both locations had been flash fro-
zen in liquid nitrogen within 5 minutes of resection and stored 
until RNA extraction. Total RNA was isolated from samples 
using a standard, spin column–based kit (RNeasy; Qiagen) and 
reverse transcribed for subsequent PCR analysis.
Statistical Analyses
For Matrigel invasion and gene expression in human tumor sam-
ples, we used the t test to calculate 95% confidence intervals (CIs) 
on differences between means and the Mann–Whitney test to 
obtain the P value. For data related to experimental bone metasta-
sis in mice, differences in osteolytic lesion areas between groups 
were determined by two-way analysis of variance with Bonferroni 
posttests (GraphPad Prism). All statistical tests were two-sided. All 
results were expressed as means with 95% confidence intervals, 
and P < .05 was considered to be statistically significant.
results
GLI2 Expression and Invasive Potential of Human Melanoma 
Cell Lines
We first determined the expression of the main HH pathway com-
ponents in a panel of 10 human melanoma cell lines by semiquan-
titative RT-PCR. GLI2 expression was highly variable: Dauv1, 
WM852, 1205Lu, and WM793 cells expressed high levels of GLI2 
mRNA (Figure 1, A, lanes 2, 6, 9, and 10), whereas in 888mel, 
501mel, and FO-1 cells (lanes 3–5), GLI2 mRNA was barely de-
tectable under the same PCR conditions. SK28, WM983B, and 
WM983A cell lines (lanes 1, 7, and 8) expressed GLI2 mRNA at 
intermediate levels, similar to those found in normal human mela-
nocytes (lane 11). Expression of PTCH1, which was previously 
identified as a GLI2 transcriptional target (36), was increased in all 
but one cell line, WM852, among those cell lines that expressed 
GLI2 mRNA at high levels, and expression of GLI1, another 
known GLI2 target (37), was also elevated in all cell lines that 
expressed high levels of GLI2 mRNA except Dauv1 cells. Sonic 
hedgehog mRNA was undetectable in all melanoma cell lines 
except 501mel, whereas it was readily detected under the same 
PCR conditions in human pancreatic adenocarcinoma cell lines 
(data not shown). Expression of SMO and GLI3, at the mRNA 
level, was similar among all melanoma cell lines. Quantitative 
RT-PCR confirmed the results of multiplex semiquantitative 
RT-PCR and determined that GLI2 mRNA expression in Dauv1, 
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WM852, 1205Lu, and WM793 cell lines was about 200-fold 
higher than that in 888mel, 501mel, or FO-1 cells, and 15-fold 
higher than that in SK28, WM983A, and WM983B cells (data not 
shown).
Western blot analysis showed that GLI2 protein was abundant 
in WM852, 1205Lu, and WM793 cells (Figure 1, B) but undetect-
able in 888mel, SK28, WM983A, WM983B, and 501mel cells. 
Also, indirect immunofluorescence staining of GLI2 protein in 
1205Lu, WM793, and WM852 cell cultures indicated that the 
GLI2 protein was almost exclusively localized in cell nuclei (data 
not shown).
Together, these results indicated that GLI2 mRNA expression 
is highly variable in human melanoma cell lines, with GLI2 protein 
content usually in accordance with steady-state levels of GLI2 
mRNA. We subsequently referred to the group of cell lines that 
exhibited both high GLI2 RNA and protein levels (ie, 1205Lu, 
WM793, and WM852 plus Dauv1 cells) as “GLI2high” cells, 
whereas all other cell lines that we used (ie, WM983A, WM983B, 
SK28, 501mel, 888mel, and FO-1) were considered to be 
“GLI2low.” GLI2 protein levels were never checked in Dauv1 
cells.
We found no obvious link between the levels of GLI2 expres-
sion and melanoma cell growth in vitro when comparing Dauv1, 
888mel, 501mel, FO-1, WM852, WM983B, WM983A, 1205Lu, 
and WM793 cell lines (data not shown). Likewise, GLI2high 
(1205Lu and Dauv1) and GLI2low (SK28, 888mel, and 501mel) 
melanoma cells lines could not be differentiated based on their 
capacity to form subcutaneous tumors in a subcutaneous xenograft 
growth assay in nude mice (data not shown).
Next, we compared the invasive capacity of melanoma cell lines 
in a Matrigel invasion assay. GLI2high cell lines (1205Lu, 
WM793, WM852, and, to a lesser extent, Dauv1) were all more 
invasive than GLI2low cell lines (Figure 1, C), suggesting a more 
aggressive phenotype.
Gelatin zymography identified markedly higher levels of 
MMP-2 secreted by the GLI2high cell lines (1205Lu, WM852, 
and, to a lesser extent, Dauv1), as compared with the GLI2low cell 
lines (WM983A, WM983B, SK28, 501mel, and 888mel; data not 
shown). MMP-2 is an extracellular matrix–degrading enzyme that 
is often used by cancer cells to invade basement membranes and 
progress toward a metastatic state (38).
Modulation of the Invasive Potential of Melanoma Cells 
by Altering GLI2 Function
To ascertain a causal relationship between GLI2 expression levels 
and melanoma cell aggressiveness, we transduced 1205Lu cells with 
a lentiviral vector carrying GLI2-specific shRNA to establish stable 
reduction of GLI2 protein expression or with a vector that expressed 
a control shRNA. GLI2 silencing resulted in approximately 85% 
reduction in GLI2 protein expression (Figure 2, A), a marked (ap-
proximately 75%) reduction in MMP-2 secretion (Figure 2, B) and 
a 50%–70% inhibition of the invasive capacity of 1205Lu cells in 
Matrigel (mean invasiveness for shGLI2 vs shCtrl, 52.6 vs 100 cells 
per six random microscopic fields, difference = 47.4, 95% CI = 37.0 
to 57.8, P = .024) (Figure 2, C). Notably, reduction of GLI2 protein 
levels also abrogated the stimulatory effect of TGF-b on MMP-2 
and MMP-9 secretion (Figure 2, B) and on Matrigel invasion (in the 
presence of TGF-b, mean invasiveness for shGLI2 vs shCtrl, 31.0 
cells per six random microscopic fields vs 161.9 cells per six fields, 
difference = 2130.9, 95% CI = 96.2 to 165.5, P = .002) (Figure 2, C). 
Furthermore, reduction of GLI2 protein levels strongly impaired 
cell motility, as visualized by the delayed closure of the gaps gener-
ated in cultured 1205Lu cell monolayers in the scratch wound assay 
(Figure 2, D), and by 85% inhibition of 1205Lu cell migration in a 
Transwell migration assay (data not shown). Similar results were 
obtained when GLI2-dependent transcription was altered in 1205Lu 
melanoma cells by means of stable expression of a dominant-negative 
mutant form of GLI2, GLI2-DC2 (29) (data not shown).
Figure 1. Expression of Sonic Hedgehog (SHH) 
pathway components in a panel of human mel-
anoma cell lines and relationship between GLI2 
levels and Matrigel invasion. Cell lines express-
ing high levels of GLI2 (GLI2high) are shown in 
red, and cell lines expressing low levels of GLI2 
(GLI2low) are shown in blue. A) Semiquantitative 
multiplex reverse transcription–polymerase 
chain reaction (RT-PCR). GLI1, GLI3, GLI2, SHH, 
Smoothened (SMO), and Patched1 (PTCH1) 
mRNA expression was measured in 10 human 
melanoma cell lines (lanes 1–10) and normal 
human epidermal melanocytes (NHEM, lane 11) 
in culture. Expression of the glyceraldehyde-3-
phosphate dehydrogenase gene, GAPDH, was 
examined as a control in the same RT-PCR 
reaction as each gene of interest. B) Western 
blot analysis. GLI2 protein levels were deter-
mined in various melanoma cell lines using 100 
µg protein per lane. Determination of GAPDH 
levels served as a loading control. C) Matrigel 
invasion assay. Melanoma cells (5 × 104) were 
added to the upper well of each Matrigel inva-
sion chamber in serum-free RPMI medium. The 
number of invading cells was counted 24 hours later using bright field microscopy at ×200 in six random fields. Experiments were performed four 
times using duplicate samples for each cell line. Statistical significance was calculated using the Mann–Whitney test. Error bars = 95% confidence 
intervals. GLI2high vs GLI2low groups: P = .016. All statistical tests were two-sided.







jnci.oxfordjournals.org   JNCI | Articles 1153
Inversely, stable expression of a constitutively active form of 
GLI2, GLI2-DN2, in the GLI2low SK28 melanoma cell line 
effectively enhanced GLI-dependent transcription (Figure 2, E) 
and dramatically increased the capacity of SK28 cells to invade 
Matrigel (mean invasiveness for GLI2-DN2–expressing SK28 cells 
vs control SK28 cells, 28.5 vs eight cells per six random micro-
scopic fields, difference = 220.5, 95% CI = 236.4 to 24.60, P = .057) 
(Figure 2, F). Taken together, these experiments establish a direct 
role for GLI2 in driving the invasive potential of melanoma cells.
GLI2 Expression Levels in Melanoma Cells and Occurrence 
of Experimental Bone Metastasis in Mice
1205Lu cells rapidly metastasize to bone in a mouse model in 
which tumor cells are inoculated into the left cardiac ventricle of 
nude mice (22). This model addresses the process of metastasis 
from the entry of tumor cells into the arterial circulation to the 
establishment of bone metastasis and tumor–bone interactions. In 
a first set of experiments, two GLI2high cell lines (1205Lu and 
WM852) and three GLI2low cell lines (888mel, SK28, and 
501mel) were compared for their capacity to form bone metasta-
ses. The two GLI2high cell lines caused osteolytic bone metastases 
in 100% of mice (seven of seven 1205Lu and eight of eight 
WM852 mice) 4 weeks after intracardiac inoculation. By contrast, 
only two of the five (40%), five of the eight (62.5%), and five of the 
seven (71.5%) mice inoculated with GLI2low cell lines SK28, 
888mel, and 501mel, respectively, developed bone metastases 
(Figure 3, A). Notably, all mice bearing GLI2low melanoma cell 
lines had statistically significantly longer survival than mice 
bearing GLI2high melanoma cell lines (mean for SK28 = 35.6 
days, 95% CI = 31.7 to 39.5; mean for 888mel = 44.4 days, 95% CI = 
38.2 to 50.6; mean for 501mel = 35.6 days, 95% CI = 28.0 to 43.2; 
mean for 1205Lu = 29.6 days, 95% CI = 28.8 to 30.3; mean for 
WM852 = 29.8 days, 95% CI = 29.2 to 30.3; mean survival for all 
GLI2high cell lines [1205Lu + WM852] = 29.7 days, mean survival 
for all GLI2low cell lines [888mel + SK28 + 501mel] = 39.1 days, 
difference = 9.4 days, 95% CI = 5.2 to 13.6, P < .001). Individual 
differences in survival were as follows: SK28 vs 1205Lu = 6 days, 
95% CI = 3.3 to 8.7, P = .01; SK28 vs WM852 = 5.9 days, 95% CI = 
3.4 to 8.3, P = .01; 888mel vs 1205Lu = 14.8 days, 95% CI = 8.7 to 
20.9, P = .001; 888mel vs WM852 = 14.6 days, 95% CI = 8.9 to 
20.3, P = .001; 501mel vs 1205Lu = 6 days, 95% CI = 20.8 to 12.8, 
P = .07; 501mel vs WM852 = 5.8 days, 95% CI = 20.4 to 12.1, 
P = .12) (Figure 3, B). Likewise, at the 4-week time point, the two-
dimensional area on x-rays that was occupied by the osteolytic 
lesions was substantially lower in mice that had been inoculated 
with GLI2low cells as compared with that in mice that had been 
inoculated with GLI2high cells (mean osteolytic tumor area for all 
GLI2high [1205Lu + WM852] vs all GLI2low [SK28 + 888mel + 
Figure 2. A role for GLI2 in melanoma cell migration and invasion. A) 
GLI2 silencing. GLI2 protein expression was silenced in 1205Lu 
human melanoma cells by infection with lentiviral particles carrying a 
short hairpin RNA (shRNA) against GLI2 (shGLI2). A nontargeting 
shRNA (shCtrl) was used as control. Relative GLI2 protein levels were 
measured by western blotting, and blots were reprobed with antibody 
to b-actin as an internal control. B) Matrix metalloproteinase (MMP)-2 
and MMP-9 secretion by 1205Lu cells expressing shGLI2 or control 
shRNAs. Cells were cultivated 72 hours in serum-free medium in the 
absence or presence of 10 ng/mL transforming growth factor-b 
(TGF-b), conditioned medium was collected and subjected to electro-
phoresis, and MMP activity was visualized by gelatin zymography. 
The experiment was repeated three times, and a representative exper-
iment is shown. C) Matrigel invasion assay. After stable transfection 
with control shRNA (shCtrl) or shGLI2, 1205Lu melanoma cells were 
incubated in the absence or presence of 10 ng/mL TGF-b. Then, 5 × 104 
cells were added to the upper well of each Matrigel invasion chamber 
in serum-free RPMI medium with or without 10 ng/mL TGF-b. The 
number of invading cells was counted 24 hours later using bright field 
microscopy at ×200 in six random fields. Results are expressed as the 
mean of two independent experiments, each performed in duplicate. 
D) Wound closure assays. Confluent monolayers of shCtrl and shGLI2 
1205Lu melanoma cells were wounded by a scratch with a pipette tip. 
Culture medium was replaced with fresh medium containing mito-
mycin (4 µg/mL) to prevent cell proliferation. Wound closure was 
monitored by phase contrast microscopy. A representative photomi-
crograph at ×200 magnification for each condition is shown. Photos 
were taken immediately (0 hours) or 48 hours after wounding. 
Experiments were repeated three times with similar results. E) GLI-
dependent transcription. SK28 human melanoma cells were stably 
transfected with either an expression vector carrying the gene for the 
constitutively active mutant, GLI2-DN2, or the empty vector (ctrl). GLI-
dependent transcription was measured by transient transfection of 
these cells with the GLI reporter construct (GLI-BS)8-luc and measure-
ment of the activity of the luciferase reporter. Results, expressed as 
relative luciferase activity, are the mean of two independent experi-
ments, each performed with duplicate samples. F) Matrigel invasion 
assays of ctrl- and GLI2-DN2–transfected SK28 melanoma cells. The 
cells described in (E) were treated as described in (C). The number of 
invading cells was counted 24 hours later using bright field micros-
copy at ×200 in six random fields. Results are expressed as the mean 
of three independent experiments, each performed in duplicate. 
Statistical analysis was performed using the Mann–Whitney test. 
Error bars are 95% confidence intervals. All statistical tests were 
two-sided.
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Figure 3. GLI2 expression in melanoma cells 
and incidence of bone metastasis in mice. A) 
Incidence of bone metastasis. Mice (n = 5–8) 
were inoculated by injection of the left cardiac 
ventricle with GLI2high melanoma cells (1205Lu 
and WM852) or GLI2low cell lines (SK28, 
888Mel, and 501Mel). The development of 
bone metastases is shown by representative 
x-ray images of the hind limbs of the mice at 4 
weeks after intracardiac inoculation. Arrows 
indicate osteolytic lesions. For each cell type, 
the percent incidence of bone metastases is 
shown. B) Mouse survival. Kaplan–Meier 
curves are shown for mice inoculated with 
various melanoma cell lines. Cells expressing 
high amounts of GLI2 (GLI2high) are shown in 
red, and cells expressing low amounts (GLI2low) 
are shown in blue. Blue squares: SK28, blue 
diamonds: 888mel, blue triangles: 501mel, red 
circles: WM852, red triangles: 1205Lu. The 
Mann–Whitney test was used to assess the dif-
ference in survival between groups. Mice inocu-
lated with GLI2low cells survived longer than 
those with GLI2 cells (mean survival for all 
GLI2high cell lines [1205Lu + WM852] = 29.7 
days, mean survival for all GLI2low cell lines 
[888mel + SK28 + 501mel] = 39.1 days, differ-
ence = 9.4 days, 95% confidence interval [CI] = 
5.22 to 13.64, P < .001). The number of mice at 
risk (for those inoculated with 1205Lu or 888mel 
melanoma cells) at days 0 and 30 and the 95% 
confidence interval for survival at 4 weeks are 
also shown. C) Osteolytic lesion area following 
intracardiac inoculation of melanoma cells in 
mice. Blue squares: SK28, blue diamonds: 
888mel, blue triangles: 501mel, red circles: 
WM852, red triangles: 1205Lu. Error bars are 
95% confidence intervals. Two-way analysis 
of variance with Bonferroni posttests ad-
justed for multiple comparisons: 1205 vs 
SK28: P < .001; 1205Lu vs 888mel: P < .001; 
1205Lu vs 501mel: P < .01; 1205Lu vs WM852: 
not significantly different (n.s.); WM852 vs 
SK28: P < .001; WM852 vs 888mel: P < .001; 
WM852 vs 501mel: P < .01; SK28 vs 888mel: 
n.s., SK28 vs 501mel: n.s., 888mel vs 501mel: 
n.s. All GLI2high (1205Lu + WM852) vs all 
GLI2low (SK28 + 888mel + 501mel): P < .001. 
Error bars reflect 95% confidence intervals. D) 
Effect of GLI2 silencing on the incidence of 
bone metastasis after intracardiac inocula-
tion. Representative x-ray images of the hind 
limbs of mice (n = 12–13) bearing bone 
metastases 4 weeks after the inoculation of 
1205Lu melanoma cells expressing either of 
two short hairpin RNAs (shRNAs) to GLI2 
(shGLI2-1 and shGLI2-2) vs control shRNA (shCtrl) are shown. Arrows 
indicate osteolytic lesions, and for each cell type, the percent inci-
dence of bone metastases is shown. E) Incidence of osteolytic metas-
tases in mice (n = 12–13) following intracardiac injection of 1205Lu 
cells that expressed GLI2 or control shRNA. The area occupied by 
osteolytic lesions on radiographs was measured by computerized 
image analysis of radiographs of the forelimbs and hind limbs at 
4 weeks postinoculation. The size of metastases from mice with the 
following is shown: black squares, cells with control shRNA (shCtrl); 
black triangles, shGLI2-1; open circles, shGLI2-2 (shCtrl vs shGLI2-1: 
P < .05; shCtrl vs shGLI2-2: P < .001). Error bars reflect 95% confi-
dence intervals.
501mel], 2.81 vs 0.93 mm2, difference = 1.88 mm2, 95% CI = 1.16 
to 2.60, P < .001; mean for 1205Lu vs SK28, 2.82 vs 0.399 mm2, 
difference = 2.42 mm2, 95% CI = 0.7 to 4.1, P < .001; mean for 
1205Lu vs 888mel, 2.82 vs 1.03 mm2, difference = 1.88 mm2, 
95% CI = 0.34 to 3.41, P < .001; mean for 1205Lu vs 501mel, 
2.82 vs 1.3 mm2, difference = 1.51 mm2, 95% CI = 0.06 to 3.09, 
P = .009; mean for WM852 vs SK28, 2.81vs 0.39 mm2, differ-
ence = 2.41 mm2, 95% CI = 0.79 to 4.03, P < .001; mean for 
WM852 vs 888mel, 2.81 vs 0.93 mm2, respectively, difference = 
1.87 mm2, 95% CI = 0.45 to 3.29, P < .001; mean for WM852 vs 
501mel, 2.81 vs 1.3 mm2, difference = 1.51 mm2, 95% CI = 0.03 
to 2.98, P = .008). There was no statistical difference between 
the mean values within each group (GLI2high, 1205Lu vs 
WM852; GLI2low: SK28 vs 888Mel, SK28 vs 501Mel, 888Mel 
vs 501Mel) (Figure 3, C). Taken together, these data demon-
strate that high GLI2 expression is associated with increased 
incidence of metastasis, larger osteolytic lesions, and increased 
morbidity.
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To determine whether there is a causal relationship between 
GLI2 expression and metastasis, two distinct populations of 
1205Lu melanoma cells in which GLI2 expression was reduced 
with shRNA were compared with mock-transduced cells for the 
development and progression of bone metastases. Bone metastases 
developed in 11 of the 12 (92%) mice inoculated with control 
shRNA-expressing 1205Lu cells, whereas only seven of the 12 
(58%) mice that received the first population of shGLI2-expressing 
1205Lu cells and four of the 13 (31%) mice that received the 
second population of shGLI2-expressing cells developed bone 
metastases (Figure 3, D). Osteolytic bone destruction, as measured 
by quantitative computerized image analysis on radiographs, was 
markedly less in mice inoculated with two distinct populations of 
shGLI2-expressing 1205Lu cells than in mice inoculated with 
control shRNA-transduced 1205Lu tumor cells (mean osteolytic 
tumor area for shCtrl vs shGLI2-1, 2.0 vs 0.73 mm2, difference = 
21.26 mm2, 95% CI = 22.07 to 20.45, P < .001; mean for shCtrl 
vs shGLI2-2, 2.0 vs 0.49 mm2, difference = 21.50 mm2, 95% CI = 
23.22 to 20.2, P = .042; mean for shGLI2-1 vs shGLI2-2, 0.73 vs 
0.49 mm2, difference = 20.24 mm2, 95% CI = 21.99 to 21.5, P = 
.27) (Figure 3, E).
These experiments demonstrate that GLI2high melanoma cells 
are more prone to form bone metastases than GLI2low cell lines 
and that reduction of GLI2 levels in GLI2high cells dramatically 
alters their ability to form bone metastases. Together, these data 
provide compelling evidence for a direct role for GLI2 in driving 
melanoma metastasis to bone.
GLI2 Expression and Mesenchymal Transition in 
Melanoma Cells
Changes in cell–cell adhesion molecules are associated with the 
acquisition of aggressive melanoma cell behavior (4,39,40). In 
normal skin, E-cadherin, encoded by the CDH1 gene, is expressed 
in melanocytes and keratinocytes and causes melanocytes to asso-
ciate with keratinocytes. As melanoma progresses from its radial 
growth phase to a vertical growth phase, E-cadherin expression is 
lost and N-cadherin becomes expressed (4,39,40). N-cadherin, 
encoded by CDH2, allows melanocytes to interact with other 
N-cadherin–expressing cells, such as dermal fibroblasts and the 
vascular endothelium, thereby increasing their motility and inva-
siveness (4,39,40). In turn, these modifications of cell–cell inter-
actions favor metastatic spreading of melanoma. Similar molecular 
changes occur during carcinoma progression in a cellular process 
often referred to as epithelial to mesenchymal transition (EMT) 
(41,42).
Among the transcription factors that are known to inhibit CDH1 
expression during EMT are SNAIL and the closely related SLUG, 
as well as TWIST and SIP1 (42). Therefore, we examined the ex-
pression of these genes in our panel of melanoma cell lines by semi-
quantitative RT-PCR. CDH1 expression was extremely variable 
(Figure 4, A). However, CDH1 expression levels were independent 
from those of SNAIL (eg, see lanes 7 and 8 vs 9 and 10). This dis-
parity suggests that elevated SNAIL expression is not sufficient per se 
to drive the loss of CDH1 expression. Remarkably, none of the 
GLI2high cell lines (Dauv1, WM852, WM793, or 1205Lu) expressed 
detectable levels of CDH1 mRNA (lanes 2, 6, 9, and 10). On the 
other hand, CDH1 mRNA was abundant in all GLI2low cell lines 
Figure 4. GLI2 expression and loss of E-cadherin in human melanoma 
cells. A) Expression of genes related to epithelial–mesenchymal transi-
tion. Total mRNA from four GLI2high human melanoma cell lines (red) 
and six GLI2low melanoma cell lines (blue) and from normal human 
epidermal melanocytes (NHEM cells) was analyzed by multiplex semi-
quantitative RT-PCR to determine GLI2, CDH1 (E-cadherin), CDH2 
(N-cadherin), SNAIL, SLUG, TWIST, and SIP1 expression. Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) gene expression was measured 
simultaneously in each PCR reaction as an internal control. Notable ex-
amples of the inverse relationship between GLI2 and CDH1 expression 
are highlighted in Dauv1, WM852, 1205Lu, and WM793 cell lines (green 
frames). B) Western blot analysis of E-cadherin protein levels in mela-
noma cell lines. E-cadherin was absent in GLI2high cell lines (red labels), 
whereas strong bands were detected in all GLI2low lines (blue labels). 
GLI2 protein levels in the same samples can be found in Figure 1, B.
(lanes 1, 3–5, 7, and 8) and in normal melanocytes (lane 11). CDH2 
mRNA was expressed in all cell lines that expressed GLI2 at either 
high or intermediate levels (lanes 1, 2, and 5–10) and followed a pat-
tern very similar to that of SNAIL mRNA. By contrast with SNAIL 
mRNA expression, steady-state levels of SLUG, TWIST, and SIP1 
mRNA were roughly identical among all melanoma cell lines.
We also performed western blots on lysates from selected mela-
noma cell lines to determine whether protein expression would be 
similar to that of mRNA. Western analysis revealed that E-cadherin 
protein levels paralleled CDH1 mRNA levels in that only GLI2low 
cell lines had detectable E-cadherin protein expression (Figure 4, B).
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GLI2 and CDH1 Expression in Human Cutaneous 
Melanoma In Vivo
We next examined GLI2 and CDH1 expression in three distinct 
sets of human melanoma samples. First, we performed in situ hy-
bridization to localize areas with high GLI2 mRNA expression in 
a panel of 20 primary cutaneous melanoma lesions from the 
Department of Pathology in Nijmegen, the Netherlands. Parallel 
sections were immunostained for E-cadherin protein localization. 
We consistently observed heterogeneous expression of GLI2 and 
CDH1 in all tumor samples (representative examples in Figure 5, A, 
and in Supplementary Figure 1, available online). Specifically, in 
situ hybridization of a GLI2 riboprobe revealed strong GLI2 
expression in the deep dermal compartment (Figure 5, A, panel e) 
but not in the superficial compartment (Figure 5, A, panel b) of the 
skin. In accordance with the expression pattern in melanoma cell 
lines (see Figure 4), tumor areas with low GLI2 expression were 
positive for presence of E-cadherin protein, as visualized by immu-
nohistochemistry (Figure 5, A, panels c and d), whereas regions 
with elevated GLI2 mRNA were E-cadherin negative (Figure 5, A, 
panels f and g). High power magnification showed that E-cadherin 
protein expression was localized to the plasma membrane in GLI2-
negative tumor cells (Figure 5, A, panel d).
Second, a panel of 17 cutaneous melanoma lymph node metas-
tases from Hôpital Ambroise Paré in Boulogne-Billancourt, 
France, was screened for the expression of GLI2 and of CDH1 by 
multiplex semiquantitative RT-PCR. Of these 17 samples, two had 
notably higher levels of GLI2 mRNA (Figure 5, B, lanes 6 and 15, 
respectively), associated with low expression of CDH1 mRNA. All 
samples exhibited similar expression levels of the calcium-binding 
protein S100A6 gene, a specific marker of neural crest–derived 
cells that was used to demonstrate the presence of equivalent 
tumor material in all samples.
Third, GLI2 and CDH1 expression were determined in 42 
randomly selected human melanoma samples from the UMDNJ 
Medical Center that represented four distinct stages of melanoma 
progression. The lowest levels of GLI2 expression were found in 
primary melanoma samples, and the highest levels were in distant 
metastases; however, these differences were not statistically signif-
icant (mean GLI2 expression in distant metastases vs primary 
tumors, 3.21 vs 1.18 relative units normalized against cyclophylin 
A (PPIA) expression, difference = 22.03, 95% CI = 25.29 to 1.23, 
P = .27) (Figure 5, C, left panel). Consistent with our findings in 
the melanoma cell lines, statistically significantly lower levels of 
CDH1 mRNA were detected in distant metastases as compared 
with primary tumors (CDH1 expression in distant metastases vs 
primary tumors, mean = 31.87 vs 123.6 relative units normalized 
against cyclophylin A; difference = 91.71, 95% CI = 28.89 to 
192.3, P = .032) (Figure 5, C, center panel).
Discussion
In this report, we analyzed the specific role played by GLI2 in human 
melanoma. We demonstrated that GLI2 expression in melanoma 
cells is highly variable. High GLI2 expression was associated with an 
invasive and metastatic phenotype in vitro and in vivo and with 
mesenchymal traits, such as loss of E-cadherin expression and 
enhanced MMP secretion. Likewise, in human melanoma tumors, 
increased GLI2 expression was associated with loss of E-cadherin 
protein expression. Taken together, these data implicate GLI2 as an 
important modulator of melanoma progression and metastasis.
Over the past several years, major advances have been made in 
the identification of genetic and environmental factors that con-
tribute to melanoma development. Defining biomarkers that are 
predictive of the risk of metastasis remains a major challenge. In 
this report, we demonstrate that GLI2 is a potent modulator of 
melanoma invasion and metastasis. Its expression is highly variable 
among human melanoma cell lines and tissue samples and is in-
versely correlated with the loss of E-cadherin protein expression. 
In functional studies, we unveil a direct role for GLI2 in driving 
melanoma cell invasiveness and metastasis. We previously identi-
fied GLI2 as a direct target of TGF-b signaling (23). Consistently, 
we found that high GLI2 expression in aggressive melanoma cell 
lines is driven, at least in part, by either autocrine or paracrine 
TGF-b signaling. Exogenous TGF-b is a potent inducer of GLI2 
expression in a variety of cell types including melanoma cells (23), 
irrespective of their basal GLI2 expression status (data not shown). 
Incubation of the GLI2high cell lines 1205Lu and WM852 with the 
TGF-b receptor-I kinase inhibitor SB431542 resulted in a three- to 
fourfold reduction in steady-state levels of GLI2 mRNA (data not 
shown). We previously demonstrated that either systemic inhibition 
of TGF-b signaling with the small molecule TGF-b receptor-I 
inhibitor, SD-208, or overexpression of an inhibitory signaling 
component, SMAD7, can inhibit melanoma cell invasion in vitro 
and reduce the occurrence of experimental bone metastases in a 
mouse model (22,43). In the assays of bone metastasis in mice, both 
SD-208 and SMAD7 overexpression dramatically reduced GLI2 
expression as retrospectively evaluated by real-time RT-PCR (data 
not shown). Likewise, in breast cancer cells, inhibition of TGF-b 
signaling also efficiently abrogated bone metastasis (33), whereas 
overexpression of GLI2 increased bone metastasis (44). Targeting 
GLI2 expression in melanoma cells by means of a specific shRNA 
dramatically reduced invasion of extracellular matrix in vitro (Figure 
2) and experimental metastasis to bone in mice (Figure 3), two pro-
cesses that are highly dependent on TGF-b signaling (21,22). Our 
findings thus provide new support for a critical role played by GLI2 
downstream of TGF-b signaling to drive melanoma metastasis.
In epithelial cancers, loss of E-cadherin protein expression is a 
hallmark of EMT. This phenomenon is a complex phenotypic 
conversion that involves changes in morphology, differentiation 
markers, and cell–cell adhesion molecules, and acquisition of a 
motile behavior (42) that is functionally associated with poor prog-
nosis in various cancers (41,45,46). Likewise, a mesenchymal tran-
sition is characteristic of melanoma switch from an early radial 
growth phase to vertical growth phase and subsequent metastasis 
(47,48). In this report, we determined that melanoma cell lines that 
exhibit high GLI2 at either the mRNA or the protein levels do not 
express E-cadherin. Reduction of GLI2 protein levels using 
shRNA provided evidence for a direct role for GLI2 in controlling 
melanoma invasion and metastasis to bone. We establish that high 
GLI2 expression in melanoma cell lines is associated with their 
metastatic potential and inversely correlated with loss of E-cadherin. 
Our expression data clearly indicate that loss of CDH1 expression 
is not necessarily associated with changes in SNAIL, SLUG, 
or TWIST expression, whereas it is consistently associated 
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with elevated steady-state levels of GLI2 mRNA (see Figure 4). 
Interestingly, the GLI1 protein, a direct GLI2 target (37), was 
shown to induce EMT in rat kidney epithelial cells via induction 
of the E-cadherin repressor, SNAIL (49). Future investigations 
will focus on the molecular events by which GLI2 controls the 
transition of melanoma cells to a mesenchymal phenotype.
Remarkably, opposite expression of GLI2 and CDH1 was also 
found in human melanoma samples. Using three independent sets 
of samples with distinct experimental approaches, we found that 
melanoma lesions express GLI2 and CDH1 at variable levels and 
that melanoma lesions are heterogeneous for GLI2 and E-cadherin 
expression and/or distribution. These findings are consistent with 
recent reports in the literature that have identified new regulators 
of melanoma progression, such as Brn2 or Dia-1, whose expression 
is also heterogeneous within tumors (50,51). E-cadherin plays a 
critical role in maintaining melanocyte interactions with epidermal 
keratinocytes and thus keeps progression to a metastatic state at 
bay. It is therefore reasonable to hypothesize that GLI2 may be a 
marker of melanoma aggressiveness; first, GLI2high melanoma 
cell lines are more invasive and metastatic than GLI2low cells, and 
second, high GLI2 expression in primary melanoma lesions was 
localized in the deeper part of the tumors and was consistent with 
a possible role for GLI2 in the progression toward an invasive 
phenotype. Larger cohorts of samples will be necessary to validate 
this observation.
Increased GLI2 expression was accompanied with statistically 
significant reduction of CDH1 expression in distant metastases as 
compared with primary melanoma tumors (Figure 5, C). In two 
sets of samples, we also examined whether more aggressive tumors 
expressed GLI2 at higher levels than less aggressive ones.
Figure 5. GLI2 expression and loss of E-cadherin 
in human melanoma lesions. A) Variously 
stained sections of a representative primary 
cutaneous melanoma are shown. Panel (a) 
shows a hematoxylin and eosin–stained section 
of the tumor at low magnification (scale bar = 
200 µm). Adjacent sections from the superficial 
(white box; panels b–d) and deep dermal (black 
box; panels e–g) layers were stained with either 
a riboprobe to detect GLI2 mRNA (panels b and 
e) or a monoclonal antibody to detect E-cadherin 
protein (panels c, d, f, and g) and are shown in 
more detail (scale bars for b, c, e, and f = 25 µm; 
for d and g = 12.5 µm). Additional photomicro-
graphs of GLI2 and E-cadherin–stained primary 
melanoma tumor sections can be found in 
Supplementary Figure 1, available online. B) 
Semiquantitative multiplex reverse transcription– 
polymerase chain reaction (RT-PCR) to deter-
mine GLI2 and CDH1 (E-cadherin) expression 
levels in total RNA extracted from a panel of 17 
frozen human melanoma lymph node metasta-
ses. Expression of the S100A6 calcium-binding 
protein and GAPDH (glyceraldehyde-3-phos-
phate dehydrogenase) genes was also deter-
mined as an internal control. Note the absence 
of CDH1 mRNA in samples strongly expressing 
GLI2. C) Real-time RT-PCR analysis of GLI2 (left 
panel) and CDH1 (right panel) expression in 42 
frozen melanoma samples classified according 
to tumor stage. DM = distant metastasis; NM = 
nodal metastasis; PT = primary tumor; RDM = 
regional dermal metastasis. Values are the 
mean of 10 samples in each group (12 for the 
DM group), each of them measured in triplicate 
and standardized relative to cyclophilin A ex-
pression. Error bars reflect 95% confidence 
intervals. P value was determined using the 
Mann–Whitney test. All statistical tests were 
two-sided.
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In making this assessment, we used clinical observations of time 
to metastasis and the extent of initial metastatic spread to define 
tumor aggressiveness. We found that the two most aggressive pri-
mary tumors and the two most aggressive distant metastatic lesions 
in this study expressed higher levels of GLI2 mRNA compared 
with their less aggressive counterparts. Inversely, in these two 
groups, the tumors that expressed the lowest levels of GLI2 
mRNA were much more indolent.
This study has several limitations. First, we demonstrated a role 
for GLI2 in the metastatic activity of melanoma cells in vitro and 
in a mouse model of bone metastasis in which the experiments 
were conducted with immunocompromised mice. Immune func-
tion may affect the growth and dissemination of melanoma in 
human patients. In future investigations, it will be important to 
study whether GLI2 targeting interferes with melanoma metasta-
sis in animal models with spontaneous metastasis. Second, we were 
not able to measure GLI2 protein levels in human tissue because 
of the lack of a suitable antibody when these studies were per-
formed, and the number of human specimens that we analyzed was 
rather small. Newly released commercial antibodies are currently 
being tested for their specificity. Once adequate antibodies become 
available, immunohistochemical analyses will be performed on 
tissues from a larger cohort of patients, with sufficient sample size 
to allow us to determine whether there is a direct correlation 
between GLI2 protein expression and histopathological staging of 
human melanoma.
Taken together, our findings provide a strong rationale to fur-
ther investigate the role of GLI2 in the initiation and progression 
of melanoma. Our future goals include the generation of genetic 
mouse models in which GLI2 function is altered specifically in the 
melanocyte lineage. It will also be very important to investigate 
whether GLI2 expression, or the GLI2 to CDH1 ratio, may be a 
marker of a more aggressive melanoma phenotype in a large 
cohort of human melanoma samples.
Supplementary Data
Supplementary data can be found at http://www.jnci.oxfordjournals 
.org/.
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